Price: 337.64

Today's Change: 4.33

Today's Percent Change: 0.23%

Today's Volume: 1360299

Average Daily Volume: 1265800

52 week low: 244.28

52 week high: 338.94

Market cap: 71390000000.0

EBITDA: 6420000000.0

EBITDA / market_cap: 8.99%

Earnings per Share (EPS): 15.24

EPS / price: 4.51%

Dividend Yield: 0.0%

Dividend per share: 0.0

Book value: 54.79

Price to Book Ratio: 6.08

Price to Earnings (P/E) Ratio: 22.16

Price to Earnings Growth (PEG) Ratio: 2.37

Price to Sales (P/S) Ratio: 6.01

Short Ratio: 2.28

Exchange: "NMS"

Short term: UP (Previous: UP)

Mid term: UP (Previous: UP)

Long term: UP (Previous: UP)

Support: 253.33

Resistance: 256.33

Pivot point: 254.81

SMA 10: 263.31

SMA 50: 275.18

SMA 100: 279.22

RSI 10: 25.48

RSI 50: 41.53

RSI 100: 46.21

EMA 10: 265.24

EMA 50: 277.66

EMA 100: 280.82

STRONG BUY

Based on 13 buy signals and 0 sell signals

Previous signal: strong buy

280.24

NEGATIVE

BIIB
BIIB

@adamfeuerstein: Biogen halts study of closely watched Alzheimer’s drug, a blow to hopes for new treatment https://t.co/ZA7wnzVMLm $BIIB

@sxbegle: No no no . . . even those who have been questioning the #amyloid hypothesis in #Alzheimers (and lamenting its hegem… https://t.co/e6Ycn3Zz7c

@FayCortez: For people who wonder why drugs are so expensive, here's the answer. $BIIB spent more than $800 million on this com… https://t.co/Nv1Z5fO6sh

@Biotech2050: RT @_B_I_O_T_E_C_H_: ARM Transcript $SGMO comments on $BIIB Biogen and the end of amyloid hope https://t.co/MEZTeQvpx2

@teaminspire: RT @RebeccaDRobbins: We put together a list of what's next in the Alzheimer's pipeline after today's $BIIB failure. This one was a team eff…

@estherzuritamd: RT @matthewherper: I'm sad about the $BIIB news, but not surprise. Alzheimer's is difficult. It's amazing the resources that have been spe…

@estherzuritamd: RT @lasbolasdeltoro: Biogen $biib elimina dos ensayos de medicamentos contra el Alzheimer y elimina $ 18 mil millones del valor de mercado.…

@Vinks_O_7: RT @LifeSciVC: Biogen has lost more value this morning (~$17B) than was raised in all 130+ biotech IPOs since Jan 2015 combined (~$15B)...…

@Jack65203: Biogen is crashing after scrapping its late-stage Alzheimer's drug trials $BIIB https://t.co/zvHNZXpmTG

@tangentstyle: Makes sense, when U look @ $BIIB, every1 dunking “1 of greatest follies in biopharma hist (...) Evidence 4 thinkin… https://t.co/S5aZqVI787

@samdegreen: RT @LifeSciVC: Biogen has lost more value this morning (~$17B) than was raised in all 130+ biotech IPOs since Jan 2015 combined (~$15B)...…

@Phoenixshanshan: RT @AndyBiotech: $BIIB Scorecard for its "high RISK high reward" R&D strategy Pretty much everything except Spinraza on this pipeline char…

@insearchofdelta: $BIIB Just remember there are living people praying for these trials to succeed for themselves or their loved ones.… https://t.co/y19KNRnsKM

@basselj1: RT @sharkbiotech: A major rule of biotech investing is to bet against any Alzheimer's drug $BIIB

@HypocritesMD: RT @LifeSciVC: Biogen has lost more value this morning (~$17B) than was raised in all 130+ biotech IPOs since Jan 2015 combined (~$15B)...…